KDM6A在髓系肿瘤中的病理作用和临床意义  

Pathological role and clinical significance of KDM6A in myeloid neoplasms

作　　者：刘子祺 钱军[1] LIU Zi-qi;QIAN Jun(Department of Hematology,the Affiliated People's Hospital of Jiangsu University,Zhenjiang 212000,China)

机构地区：[1]江苏大学附属人民医院血液科,江苏镇江212000

出　　处：《中国病理生理杂志》2022年第11期2093-2097,共5页Chinese Journal of Pathophysiology

基　　金：国家自然科学基金项目(No.81970118);江苏省医学创新团队(No.CXTDB2017002);镇江市血液病临床医学研究中心(No.SS2018009)。

摘　　要：赖氨酸去甲基化酶6A(lysine demethylase 6A,KDM6A)在20多年前首次被发现,于2007年被鉴定为特异性组蛋白去甲基化酶[1],能去除组蛋白H3第27位赖氨酸三甲基化(H3K27me3)修饰的抑制作用,对生理造血有重要意义。髓系肿瘤是骨髓内异常造血干祖细胞(hematopoietic stem and progenitor cell,HSPC)的克隆性增生。复发和耐药是多数患者总体预后较差的主要原因。KDM6A通过表观修饰作用调控关键基因和信号通路,从而影响髓系肿瘤的发生和预后。Lysine demethylase 6A(KDM6A)contributes to the growth and development of normal tissues through demethylation. Despite this,its abnormal expression is involved in the process of a variety of malignant tumors. In many solid tumors,accumulated evidence has validated KDM6A as a biomarker in the cancer diagnosis and prognosis. In the hematopoietic system,KDM6A promotes hematopoietic lineage differentiation,regulates immune-related pathways,maintains hematopoietic homeostasis,and so on. However,the aberration of KDM6A leads to drug resistance and relapse of myeloid neoplasms,thus resulting in poor survival. This paper summarizes the physiological and pathological role of KDM6A in the hematopoietic system,and the clinical significance of its abnormal expression in myeloid neoplasms,highlighting the recent in vitro and in vivo studies of KDM6A and providing reference for identifying new therapeutic targets for myeloid neoplasms.

关 键 词：赖氨酸去甲基化酶6A 髓系肿瘤 去甲基化 突变 

分 类 号：R551.3[医药卫生—血液循环系统疾病] R363.2[医药卫生—内科学]